Skip to main content
CSL Ltd. logo

CSL Ltd. — Investor Relations & Filings

Ticker · CSL ISIN · AU000000CSL8 LEI · 529900ECSECK5ZDQTE14 ASX Manufacturing
Open in API
Filings indexed 2,555 across all filing types
Latest filing 2008-12-11 Director's Dealing
Country AU Australia
Listing ASX CSL

About CSL Ltd.

https://www.csl.com/

CSL is a global biotechnology company that researches, develops, manufactures, and markets a diverse portfolio of medicines. The company operates through distinct business units. CSL Behring provides plasma-derived and recombinant biotherapies for patients with rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders. CSL Seqirus is a leading provider of vaccines, with a focus on influenza prevention and public health. CSL Vifor specializes in therapies for iron deficiency and nephrology, addressing the full spectrum of kidney disease. Collectively, CSL delivers lifesaving and life-enhancing treatments to a global patient population.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's acquisition of shares, including dates, number of shares before and after the change, and consideration paid. This is a report of personal share transactions by a company director. The document length is short and focused solely on director share dealings, with no financial statements or other report content. Therefore, it fits the definition of Director's Dealing (DIRS).
2008-12-11 English
CSL Research and Development Briefing 52 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed R&D briefing presentation from December 2008, covering research and development strategy, pipeline, product updates, clinical trials, manufacturing, and collaborations. It includes extensive scientific and product development information, pipeline status, and strategic focus areas. There is no indication that this is an earnings release, annual report, or regulatory filing. It is not a transcript of a call, nor a voting or board management announcement. The content is a presentation aimed at informing stakeholders about R&D progress and strategy, which fits the definition of an Investor Presentation (IP). The document length and detail confirm it is the presentation itself, not just an announcement of a report.
2008-12-10 English
Appendix 3B 7 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, issue price, purpose, and quotation application to the ASX. It references specific rules (2.7, 3.10.3, etc.) related to new issue announcements and includes a quotation agreement section. The document is a formal announcement of new share issuance and application for quotation of additional securities, consistent with regulatory filings for capital changes. It does not contain financial statements or management discussion, nor is it a report or presentation. The content aligns with announcements about new share issues and capital changes rather than a full report or other categories.
2008-12-09 English
Appendix 3B 7 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including the number of shares, issue price, purpose, and quotation application to the ASX (Australian Securities Exchange). It references specific ASX rules and includes sections on securities issued, terms, and quotation agreements. The document is a formal announcement of a new share issue and application for quotation rather than a financial report or earnings release. It fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes.
2008-12-04 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about changes in a director's relevant interests in securities, including the number of shares, performance rights, and options held before and after the change. It references ASX listing rules and the Corporations Act, indicating it is a regulatory filing related to insider transactions. The content focuses on the personal share transactions of a company director, which aligns with the definition of 'Director's Dealing' filings. The document length is 3482 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the document is classified as a Director's Dealing report.
2008-12-04 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and details changes in securities holdings by a director, including performance rights and options. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure of insider transactions. The content focuses on the director's personal share transactions and changes in interests, not on financial results, management changes, or other report types. The document length is 3482 characters, which is typical for such notices. Therefore, this document fits the category of Director's Dealing (DIRS).
2008-12-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.